Islet Sciences, Inc. (OTCBB: ONCE) is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immuno-protection (microencapsulation) of islet cells. Islet Sciences’ mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.
The Company announced that George J. Todaro, M.D. and Jerry L. Nadler, M.D. have been named to its Board of Directors. Dr. Todaro and Dr. Nadler join Joel D. Perlin, Dr. Jonathan Lakey and John Steel to the company's Board of Directors.
George Todaro is a renowned research scientist and medical doctor who "co-authored the groundbreaking 'Oncogene Theory' while at the National Institute of Health (NIH) in 1969, which would serve as one of the foundations for future cancer research. In the early 1990s, as scientific director at Seattle-based PathoGenesis, he developed a treatment that has saved the lives of countless cystic fibrosis patients." Most recently, he has focused on biotechnology and on ways to increase the world's food supply. Dr. Todaro "is a member of the National Academy of Sciences, holds over 20 patents and has served as professor and department head at the University of Washington."
Dr. Jerry L. Nadler is Professor and Chairman of Internal Medicine and the Harry H. Mansbach Endowed Chair in Internal Medicine, as well as Director of the Strelitz Diabetes Center at Eastern Virginia Medical School. Additionally, he is the Scientific Founder of DiaKine, a company developing therapies for type 1 and type 2 diabetes and related complications. Dr. Nadler currently "serves as a Pfizer Visiting Professor in Diabetes. Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the National Institutes of Health Diabetes Institute and was the Associate Director of the NIH-funded Diabetes Endocrinology Research Center at the University of Virginia. Dr. Nadler has research funding from the Juvenile Diabetes Foundation, The Ella Fitzgerald Charitable Foundation and the Iacocca Foundation. He is a standing member of the ADA and NIH grant review committees."
John Steel, Chairman and CEO of Islet Sciences, commented,
"George and Jerry bring distinctively different but equally important skill sets to our Board. George's wealth of experience and success in researching and discovering real-world treatments for cancer and cystic fibrosis are a perfect fit for our company as Islet Sciences works toward a practical treatment for diabetes. Jerry brings not only the academic's perspective but also the knowledge and insights gained as an involved scientific founder for diabetes therapies as well as an active member or director to several esteemed institutions. I look forward to their counsel and expertise in driving the success of Islet Sciences."